Suspended

TREAT-PVCLow-Level Tragus Stimulation for Frequent Premature Ventricular Contractions

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Low-level tragus stimulation

+ Sham stimulation

Device
Who is being recruted

Cardiac Conduction System Disease+5

+ Arrhythmias, Cardiac

+ Cardiovascular Diseases

From 18 to 80 Years
+15 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Placebo-Controlled
Interventional
Study Start: March 2021
See protocol details

Summary

Principal SponsorThe First Affiliated Hospital with Nanjing Medical University
Study ContactGang MD YangMore contacts
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: March 15, 2021

Actual date on which the first participant was enrolled.

This study focuses on a common type of irregular heartbeat known as Premature Ventricular Contraction (PVC). PVCs can potentially harm patients by increasing the risk of heart disease, triggering other serious heart rhythms, and worsening existing heart conditions. Currently, treatment for PVCs primarily involves medication, but effectiveness varies greatly among individuals. The study aims to explore a new, non-invasive method called low-level tragus stimulation (LLTS) to manage PVCs. This method involves stimulating the vagus nerve through the tragus of the ear, which has shown promise in reducing symptoms related to heart conditions and other disorders. The study is designed as a randomized, single-blind trial involving 100 patients. Participants are divided into two groups: one receiving active LLTS and the other receiving a sham treatment. The active LLTS is administered using a device called the Parasym device, which stimulates the vagus nerve through an ear clip attached to the tragus. The sham treatment involves attaching the clips to the earlobe, which does not affect the vagus nerve. Patients' heart activity is monitored at baseline, 3 months, and 6 months using a non-invasive, adhesive ECG patch. The study measures the burden of PVCs, or the percentage of premature ventricular beats in total heartbeats. Additionally, it evaluates heart rate variability, quality of life, skin sympathetic nerve activity, and serum cytokine levels at baseline and follow-up.

Official TitleTranscutaneous Electrical Vagus Nerve Stimulation to Suppress Premature Ventricular Contractions
NCT04909528
Principal SponsorThe First Affiliated Hospital with Nanjing Medical University
Study ContactGang MD YangMore contacts
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

100 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 80 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Cardiac Conduction System DiseaseArrhythmias, CardiacCardiovascular DiseasesCardiac Complexes, PrematureHeart DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsVentricular Premature Complexes

Criteria

4 inclusion criteria required to participate
Age >18, <80 of age

Symptomatic PVCs refractory to ≥1 antiarrhythmic drugs (including β-blockers and calcium-channel blockers).

PVC burden ≥ 10%, with or without prior ablation

Arrhythmias originated from any focus (foci) in the right ventricular or left ventricular.

11 exclusion criteria prevent from participating
Left ventricular ejection fraction (LVEF) < 45% unless proven to be PVC-mediated cardiomyopathy (history of improving LVEF by >15% when PVC burden was reduced by pharmacological agents or ablation)

EF continues to decrease in the past 4 months regardless of the etiology

Unwilling to continue current pharmacological therapy during the study period

Severe heart failure with New York Heart Association Class ≥ III

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

50% chance of being blinded to the placebo group

Treatment Groups

Group I

Experimental
Low-level tragus stimulation

Group II

Sham
Sham stimulation

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

The First Affiliated Hospital of Nanjing Medical University

Nanjing, ChinaOpen The First Affiliated Hospital of Nanjing Medical University in Google Maps
SuspendedOne Study Center